Pharming (PHAR) Non-Current Deferred Tax Liability (2019 - 2025)

Pharming (PHAR) has 7 years of Non-Current Deferred Tax Liability data on file, last reported at -$31.0 million in Q4 2025.

• Quarterly Non-Current Deferred Tax Liability fell 1.55% year-over-year to -$31.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$31.0 million (down 1.55% YoY) and the FY2025 annual result came in at -$31.0 million, down 1.55% from the prior year.
• Non-Current Deferred Tax Liability fell to -$31.0 million in Q4 2025, from -$30.5 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of -$21.2 million in Q4 2021 to a low of -$31.0 million in Q4 2025.
• A 5-year average of -$27.1 million and a median of -$29.8 million in 2023 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2021 — Non-Current Deferred Tax Liability soared 31.45% — and 2023, when it slipped 29.55%.
• Tracing PHAR's Non-Current Deferred Tax Liability over 5 years: stood at -$21.2 million in 2021, then slipped by 8.28% to -$23.0 million in 2022, then fell by 29.55% to -$29.8 million in 2023, then dropped by 2.63% to -$30.5 million in 2024, then declined by 1.55% to -$31.0 million in 2025.
• The last three Non-Current Deferred Tax Liability figures came in at -$31.0 million (Q4 2025), -$30.5 million (Q4 2024), and -$29.8 million (Q4 2023), per Business Quant data.